# Aptorum Group Limited

Type: Company (APM)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/aptorum-group-limited
Canonical HTML page: https://getbiobrief.com/entity/aptorum-group-limited

## Timeline

- **2026-Q4**: Potential Extension — Aptorum may apply for a second 180-day period if compliance is not met but criteria are satisfied.
- **2026-09-02**: Initial Compliance Deadline — End of the first 180-day grace period to regain a $1.00 closing bid price.
- **2026-03-06**: Deficiency Notice Received — Nasdaq notifies Aptorum of non-compliance with the $1.00 minimum bid price rule.

## Recent coverage (1 stories)

### Aptorum Faces Nasdaq Delisting Risk Amid Minimum Bid Price Deficiency
2026-03-06 22:24:58 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Aptorum Group Limited (APM) has received a formal deficiency notice from Nasdaq for failing to maintain the $1.00 minimum bid price required for continued listing. The company now enters a critical 180-day window to regain compliance, highlighting the ongoing financial pressures facing small-cap clinical-stage biotech firms.
Full story: https://getbiobrief.com/story/aptorum-nasdaq-minimum-bid-price-deficiency

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.